Testosterone for Midlife Women: New ALEG Guidelines Explained

Introduction

The prescription of testosterone for midlife women, especially for symptoms like low libido, is common but often lacks clear clinical guidelines. A new position statement from the Latin American Association of Gynecological Endocrinology (ALEG) systematically analyzes the evidence for androgen therapy, delivering specific recommendations on when and how it should be used, and offering a clear warning about certain so-called “bioidentical” products.

Bioidentical Androgen Products Face Scrutiny for Safety

The Latin American expert panel, led by Dr. Sergio Pilnik of the Hospital Italiano de Buenos Aires, gave compounded “bioidentical” testosterone a direct, low-grade recommendation against its use. They cited significant risks, including a high potential for supraphysiological dosing—meaning the hormone levels can soar far above a normal female range. Unlike commercially manufactured, regulated transdermal gels or patches, compounded products from special pharmacies are not standardized. Their potency and absorption can vary between batches, making it difficult to achieve a safe, consistent dose. This lack of evidence for safety and efficacy led the authors to state these formulations should not be used.

The issue is particularly pressing in Latin America, where no androgenic products are specifically approved for women. The statement notes this leads to the use of products designed for men or non-standardized formulations, increasing patient risk. The group’s goal is to promote good medical practice by discouraging these unregulated options in favor of evidence-based approaches.

Testosterone’s Narrow Path: From Diagnosis to Monitoring

The position statement, based on Cochrane reviews, meta-analyses, and international guidelines published since 2000, carves a very narrow and defined role for medical testosterone therapy. Its sole Grade A (High) recommendation is for treating postmenopausal women with HSDD, and only after a “formal biopsychosocial evaluation.” This critical step rules out other causes of low libido, such as relationship issues, stress, depression, or other medical conditions, ensuring testosterone is appropriate.

Contrary to popular belief, the panel strongly advises against using routine blood tests of testosterone or other androgens to diagnose a deficiency in women. Hormone levels fluctuate and correlate poorly with symptoms. However, they do recommend checking a baseline level before starting therapy for a different reason: to exclude women who already have elevated concentrations, which could be worsened by treatment. Once therapy begins, monitoring within 3-6 weeks is advised to ensure blood levels stay within the premenopausal physiological range, a safeguard against potential side effects like acne, hair growth, or voice changes.

A Firm No to Systemic DHEA Supplements

Beyond testosterone, the ALEG statement addresses another popular androgen: dehydroepiandrosterone (DHEA). Often marketed as an over-the-counter supplement for vitality, libido, and wellbeing, oral DHEA received a Grade A (High) recommendation against its systemic use for sexual symptoms. The panel concluded current evidence does not support its effectiveness. DHEA is a precursor hormone the body can convert into both estrogen and testosterone, but its conversion is inefficient and unpredictable, leading to inconsistent results and potential side effects.

The experts make a vital distinction: vaginal DHEA (prasterone) is a separate, approved pharmaceutical product specifically for treating the genitourinary syndrome of menopause, such as vaginal dryness and pain. This localized treatment is not the same as taking oral DHEA supplements intended for whole-body effects.

What This Means for Treatment Decisions

For women considering androgen therapy for menopause-related symptoms, this position statement creates a framework for safer, more effective care. It elevates the importance of a thorough clinical assessment over a simple blood test. It also directs patients and clinicians toward regulated, transdermal formulations and away from riskier compounded products that lack quality control.

Open, informed counseling is a cornerstone of the recommendations. Clinicians are urged to explain that testosterone for female HSDD is an off-label use, meaning it is prescribed based on evidence but not formally approved by regulatory agencies for that specific condition. This transparency allows for shared decision-making. While the guidelines are specific to androgen therapy, a holistic approach to menopause health remains key. Research confirms that regular exercise can significantly ease core symptoms like hot flashes and sleep disturbances, serving as a foundational pillar of management alongside any medical treatments.

Conclusion

The ALEG position statement clarifies a complex and often confusing area of menopause care. It restricts medically-supervised testosterone therapy to a specific group of women with HSDD, advocates for safer administration methods, and warns against unregulated compounded products and ineffective systemic DHEA supplements. This evidence-based approach aims to protect women from potential harm while providing a clear path for those who may benefit.

Sources:
https://pubmed.ncbi.nlm.nih.gov/40919649/
https://pubmed.ncbi.nlm.nih.gov/40109076/
https://pubmed.ncbi.nlm.nih.gov/38980733/